A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE005 (FRA) · Dr. Muller
consented 2022-06-16
AEs
4
Serious
0
Dropout signal
–
Adverse events
moderate
assessed
Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-07-30 (study day 34); relationship: not assessed
mild
assessed
Grade 1 Fatigue — outcome: RECOVERED/RESOLVED; onset 2023-01-23 (study day 211); relationship: Y
moderate
assessed
Grade 2 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2023-08-27 (study day 427); relationship: not assessed
moderate
assessed
Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-11-30 (study day 522); relationship: not assessed
Data queries
No data queries.